A Study to Learn About the Study Medication Called Etrasimod Mini Tablets, Including Its Taste, When Mixed With Applesauce, Chocolate Pudding, Yogurt or Water in Healthy Participants

Trial details

Who runs it

Pfizer Inc.

Trial code

EU 2023-504411-32-00

Record updated

2023. augusztus 2.

Original description

- To estimate the rBA of etrasimod 2 mg mini tablets mixed with water compared to etrasimod 2 mg clinical IR tablets under fasted conditions - To estimate the rBA of the etrasimod 2 mg mini tablets mixed with applesauce compared to the etrasimod 2 mg clinical IR tablets under fasted conditions - To estimate the rBA of the etrasimod 2 mg mini tablets mixed with chocolate pudding compared to the etrasimod 2 mg clinical IR tablets under fasted conditions - To estimate the rBA of the etrasimod 2 mg mini tablets mixed with yogurt compared to the etrasimod 2 mg clinical IR tablets under fasted conditionsRead full original descriptionShow less

C5041034 - A Phase 1, Open-Label, Randomized, Single Dose, Crossover Study to Estimate the Relative Bioavailability of Etrasimod (PF-07915503) Mini Tablets in Water and 3 Food Vehicles Compared to the Etrasimod (PF-07915503) Clinical IR Tablets Under Fasted Conditions, and to Evaluate Mini Tablet Palatability in Healthy Adult Participants

- To estimate the rBA of etrasimod 2 mg mini tablets mixed with water compared to etrasimod 2 mg clinical IR tablets under fasted conditions - To estimate the rBA of the etrasimod 2 mg mini tablets mixed with applesauce compared to the etrasimod 2 mg clinical IR tablets under fasted conditions - To estimate the rBA of the etrasimod 2 mg mini tablets mixed with chocolate pudding compared to the etrasimod 2 mg clinical IR tablets under fasted conditions - To estimate the rBA of the etrasimod 2 mg mini tablets mixed with yogurt compared to the etrasimod 2 mg clinical IR tablets under fasted conditions

Inclusion: Male and female participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at screening who are overtly healthy as determined by medical evaluation including a detailed medical history, full physical exam, which includes BP and pulse rate measurement, clinical laboratory tests, temperature, and 12-lead ECG; BMI of 16 to 32 kg/m2; and a total body weight >50 kg (110 lb); Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures; Capable of giving signed informed consent.

Exclusion: History of febrile illness within 5 days prior to the first dose of study intervention; Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, anaphylactic, ophthalmologic disorder (such as macular edema, uveitis, retinopathy), or allergic disease; Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy); Known immunodeficiency disorder, including positive serology for HIV, or a first degree relative with a hereditary immunodeficiency; Infection with hepatitis B or hepatitis C viruses according to protocol specific testing algorithm history; Participants with any of the specified acute or chronic infections or infection history; History of any lymphoproliferative disorder such as EBV related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs or symptoms suggestive of current lymphatic or lymphoid disease; Known present or a history of malignancy other than a successfully treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ; Evidence of untreated or inadequately treated active or latent Mycobacterium TB infection.

EU CTIS 2023-504411-32-00